Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
3.920
-0.300 (-7.11%)
Oct 23, 2026, 4:00 PM EDT - Market closed
Adial Pharmaceuticals Employees
Adial Pharmaceuticals had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Adial Pharmaceuticals the 41,686th largest employer in the world and 6,479th in the United States.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$11,560,234
Market Cap
10.29M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - | 5 | 0 |
| Dec 31, 2024 | 5 | 1 | 25.00% | 5 | 0 |
| Dec 31, 2023 | 4 | -16 | -80.00% | 4 | 0 |
| Dec 31, 2022 | 20 | -1 | -4.76% | 16 | 4 |
| Dec 31, 2021 | 21 | 12 | 133.33% | 16 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Palatin Technologies | 25 |
| Passage Bio | 24 |
| BioLineRx | 24 |
| Citius Pharmaceuticals | 23 |
| Lipocine | 14 |
| Cellectar Biosciences | 11 |
| Purple Biotech | 10 |
ADIL News
- 3 days ago - Adial Pharmaceuticals Registration statement: Registration filing - Filings
- 8 days ago - Adial Pharmaceuticals Proxy statement: Proxy filing - Filings
- 8 days ago - Adial Pharmaceuticals appoints David Rubenstein as chief scientist - TheFly
- 8 days ago - Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis - GlobeNewsWire
- 19 days ago - Adial Pharmaceuticals Proxy statement: Proxy filing - Filings
- 24 days ago - Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Adial Pharmaceuticals Proxy statement: Proxy filing - Filings
- 5 weeks ago - Adial Pharmaceuticals Proxy statement: Proxy filing - Filings